Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Renal Cell Carcinoma 1

Interventions

pembrolizumab 23Gemcitabine 14Carboplatin 10Nivolumab 9Cyclophosphamide 9olaparib 8Specimen Handling 8Paclitaxel 8Trastuzumab 7Magnetic Resonance Spectroscopy 6fludarabine 5Standard of Care 5Irinotecan 5Ipilimumab 5Docetaxel 5Cisplatin 5Capecitabine 5Biopsy 5sargramostim 4pertuzumab 4palbociclib 4enzalutamide 4durvalumab 4atezolizumab 4aldesleukin 4Taxes 4Oxaliplatin 4Fluorouracil 4Erlotinib Hydrochloride 4Early Intervention, Educational 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × balstilimab × Genitourinary × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

Phase 1/2 Recruiting
71 enrolled
GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡